ReviewJournal of immunology (Baltimore, Md. : 1950)2014
Thymic stromal lymphopoietin and cancer.
Review in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- TSLP: contrasting roles in cancer.Frontiers in immunology · 2025Review
- IL22RA1/JAK/STAT Signaling Acts As a Cancer Target Through Pan-Cancer Analysis.Frontiers in immunology · 2022Article
- The correlation between single nucleotide polymorphisms of the thymic stromal lymphopoietin receptor and breast cancer in a cohort of female patients in Saudi Arabia.Environmental science and pollution research international · 2021Article
- Article
- Article
- Increased Expression of Thymic Stromal Lymphopoietin in Chronic Constriction Injury of Rat Nerve.International journal of molecular sciences · 2021Article
- Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.Medical oncology (Northwood, London, England) · 2020Review
- Yupingfeng Granule Improves Th2-Biased Immune State in Microenvironment of Hepatocellular Carcinoma through TSLP-DC-OX40L Pathway.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.Frontiers in immunology · 2020Review
- Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer.Frontiers in immunology · 2020Review
- Dysfunction of antigen processing and presentation by dendritic cells in cancer.Molecular immunology · 2019Review
- Dendritic Cell-Mediated Th2 Immunity and Immune Disorders.International journal of molecular sciences · 2019Review
- Expression and Regulation of Thymic Stromal Lymphopoietin and Thymic Stromal Lymphopoietin Receptor Heterocomplex in the Innate-Adaptive Immunity of Pediatric Asthma.International journal of molecular sciences · 2018Review
- The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages.Immunologic research · 2018Article
- Detection of Minimal Bone Marrow involvement of Blastic Plasmacytoid Dendritic Cell Neoplastic Cells - CD303 immunostaining as a diagnostic tool.Journal of clinical and experimental hematopathology : JCEH · 2018Article
- Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model.Cancer immunology, immunotherapy : CII · 2018Article
- IL-2 and Beyond in Cancer Immunotherapy.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2018Review
- Thymic stromal lymphopoietin drives the development of IL-13Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution.
Funding
Abstract
Originally shown to promote the growth and activation of B cells, thymic stromal lymphopoietin (TSLP) is now known to have wide-ranging effects on both hematopoietic and nonhematopoietic cell lineages. These include dendritic cells, basophils, mast cells, B cells, epithelial cells, and CD4(+), CD8(+), and NK T cells. Although TSLP's role in the promotion of Th2 responses has been studied extensively in the context of lung- and skin-specific allergic disorders, it is becoming increasingly clear that TSLP may impact multiple disease states within multiple organ systems. This review highlights recent advances in the understanding of the surprising role of TSLP in the control of a variety of cancers, both solid tumors and leukemia, in which the TSLP/TSLP receptor axis was shown to be an important regulator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.